Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants

被引：0
|
作者：
Anderson, Kacey [1 ]
Holes, Leanne [1 ]
Marmon, Tonya [1 ]
Nichols, Andie [1 ]
Schlegel, Amnon [1 ]
Nelson, Cara [1 ]
Kuriakose, Emil [1 ]
机构：
[1] Terns Pharmaceut, Foster City, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CML; TERN-701; allosteric BCR-ABL1 tyrosine kinase inhibitor; phase; 1; safety;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-396
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [1] Tern-701 (HS-10382) Is a Potent Inhibitor of BCR::ABL1 and Is Synergistic with Active Site Tyrosine Kinase Inhibitors
    Parsons, Benjamin M.
    Jasper, Jeffrey R.
    Jones, Christopher
    BLOOD, 2023, 142
  • [2] Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
    Tanaka, C.
    Yin, O. Q. P.
    Sethuraman, V.
    Smith, T.
    Wang, X.
    Grouss, K.
    Kantarjian, H.
    Giles, F.
    Ottmann, O. G.
    Galitz, L.
    Schran, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) : 197 - 203
  • [3] The Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+Cancer Cell Lines
    Parsons, Benjamin
    Jones, Christopher
    Sun, Danni
    Li, Yunfan
    Lian, Xiaogang
    Wang, Xiaolei
    Sun, Yundong
    Zhou, Yuanfeng
    Jasper, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S350 - S350
  • [4] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1031 - 1037
  • [5] Efficacy of HS-10382 (TERN-701) in tumor xenograft models, a new investigational allosteric ABL1 kinase inhibitor as a potential treatment for CML
    Zhou, Yuanfeng
    Parsons, Benjamin
    Sun, Danni
    Li, Yunfan
    Chen, Guoliang
    Luo, Mingjie
    Jones, Christopher
    Lian, Xiaogang
    Wang, Xiaolei
    Sun, Yundong
    Jasper, Jeffrey
    Niu, Huifeng
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [6] Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells
    Tao, Wenjing
    Mak, Po Yee
    Andreeff, Michael
    Carter, Bing Z.
    BLOOD, 2017, 130
  • [7] Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects.
    Kagan, M
    Tran, P
    Fischer, V
    Savage, P
    Smith, T
    Tanaka, C
    Schran, H
    Narurkar, M
    Alland, L
    BLOOD, 2005, 106 (11) : 302B - 302B
  • [8] SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR HM71224 IN HEALTHY SUBJECTS
    Yoon, Y. -K.
    Hadi, S.
    Iersel, T. V.
    Sin, H. J.
    Lee, K. O.
    Lee, J.
    Song, J. Y.
    Jang, S.
    Lee, Y. -M.
    Kang, J.
    Suh, K. H.
    Son, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 231 - 231
  • [9] Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study
    Prokopienko, Alexander J.
    Wang, Junyao
    Yajnik, Vijay
    Baratta, Mike
    Desai, Nirav K.
    Richmond, Camilla A.
    Suri, Ajit
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (02): : 217 - 225
  • [10] Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of Tofacitinib, a Janus Kinase Inhibitor, in Healthy Volunteers
    Krishnaswami, Sriram
    Boy, Mary
    Chow, Vincent
    Chan, Gary
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (02): : 83 - 88
12345